Pityriasis rosea after Moderna mRNA-1273 vaccine: A case series
- PMID: 34816549
- PMCID: PMC9286452
- DOI: 10.1111/dth.15225
Pityriasis rosea after Moderna mRNA-1273 vaccine: A case series
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
Comment in
-
The significance of investigating clinical, histopathologic and virological features in pityriasis rosea and pityriasis rosea-like eruptions following COVID-19 vaccinations.Dermatol Ther. 2022 Aug;35(8):e15601. doi: 10.1111/dth.15601. Epub 2022 Jun 13. Dermatol Ther. 2022. PMID: 35622411 Free PMC article. No abstract available.
-
Reply to "the significance of investigating clinical, histopathologic and virological features in pityriasis rosea and pityriasis rosea-like eruptions following COVID-19 vaccinations" by Ciccarese G. et al.Dermatol Ther. 2022 Aug;35(8):e15602. doi: 10.1111/dth.15602. Epub 2022 Jun 13. Dermatol Ther. 2022. PMID: 35622446 Free PMC article. No abstract available.
References
-
- Stingeni L, Bianchi L, Zalaudek I, et al. Adverse cutaneous and mucous reactions from anti SARS‐CoV‐2 vaccines: recommendations from the Italian Society of Dermatology (SIDeMaST). Ital J Dermatol Venerol. 2021;156(2):115‐117. - PubMed
-
- Stingeni L, Bianchi L, Tramontana M, et al. Skin tests in the diagnosis of adverse drug reactions. Ital J Dermatol Venereol. 2020;155(5):602‐621. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical